Self-Reported Effects of Medical Cannabis on Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series

To observe the effect of cannabis on fibromyalgia illness severity and related symptoms of depression and anxiety. A retrospective chart review was conducted to identify all patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and completed at least 1 follow-up visit at Harvest Medicine clinics from January 2017 to July 2021. Data extracted from patient charts included Patient Health Questionnaire-9 (PHQ-9) scores, Generalized Anxiety Disorder-7 (GAD-7) scores, and self-reported illness severity scores. Changes in these scores between a patient’s intake and first follow-up visits were calculated and analyzed for significance overall and in different demographic subgroups. Patients for whom no follow-up data were available were excluded.

Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry

There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health-related quality of life and incidence of adverse events of those prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia.  Patients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient-reported outcome measures (PROMs). A p-value of <.050 was deemed statistically significant.

A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?

Analysis of over 100 Cannabis samples quantified for terpene and cannabinoid content and genotyped for over 100,000 single nucleotide polymorphisms indicated that Sativa- and Indica-labelled samples were genetically indistinct on a genome-wide scale. Instead, we found that Cannabis labelling was associated with variation in a small number of terpenes whose concentrations are controlled by genetic variation at tandem arrays of terpene synthase genes.

Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.
To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

To describe the prevalence and patterns of cannabidiol (CBD) use in women with co-existing chronic pelvic pain (CPP) and fibromyalgia, and to evaluate characteristics associated with pain improvement.

Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Authors Carolina Chaves, MD, Paulo Cesar T Bittencourt, MD, MSc, Andreia Pelegrini, PhD Published in Pain Medicine October 2020 Abstract Objective To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis…

Fibromyalgia and the endocannabinoid system

Authors: John M. McPartland Published in Science Direct November 2009 Introduction Fibromyalgia has been characterized as an ‘endocanna- binoid (eCB) deficiency syndrome’, along with other refractory maladies such as irritable…

Cannabis and Cannabidiol (CBD) for the Treatment of Fibromyalgia

Authors: Amnon A.Berger MD, PhD, Joseph Keefe BM, Ariel Winnick MA, Elasaf Gilbert BS, Jonathan P.Eskander MD, MBA, Cyrus Yazdi MD, Alan D.Kaye MD, PhD, Omar Viswanath MD, Ivan Urits…

Medical Cannabis for the Treatment of Fibromyalgia

Author: George Habib, Suheil Artul Published in Journal of Clinical Rheumatology August 2018 Abstract Background Background: Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances….

Medical Cannabis for the Treatment of Fibromyalgia

Authors: George Habib, Suheil Artul Published in Journal of Clinical Rheumatology August 2018 Abstract Background Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There…

Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study.

Authors: Valeria Giorgi, Sara Bongiovanni, Fabiola Atzeni, Daniela Marotto, et al
Clinical and experimental rheumatology, January-February 2020

OBJECTIVES: To assess any clinical improvement attributable to the addition of medical cannabis treatment (MCT) to the stable (>3 months) standard analgesic treatment of fibromyalgia (FM) patients, the retention rate and any changes in the concomitant analgesic treatment over …

Safety and Efficacy of Medical Cannabis in Fibromyalgia.

Authors: Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra, Victor Novack
Journal of Clinical Medicine, 5 June 2019

BACKGROUND: Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and effectiveness of medical cannabis thera…

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…